Professor Kathleen Schmainda presents her research to Proactive London, she is also the co-founder of Imaging Biometrics, IQAI’s subsidiary in Wisconsin, USA.
IQ-AI is now looking forward to start the clinical trials after finding a supplier to encapsulate the drug candidate. As Schmainda explains, the production of the capsules is now underway and IQ-AI anticipate the trial to commence in February 2022.
IQAI was created to accelerate the translation and commercialisation of proven imaging technologies, from the laboratory to routine clinical use, that have potential to dramatically impact the quality of life for patients facing brain tumours and other chronic diseases.